Global X FTSE Andean 40 ETF AND
No live quote for AND yet.
News
benzinga.com Teva Pharmaceuticals International Granted Exclusive Rights To Commercialize Formulations For Polpharma Biologics’ Proposed Biosimilar To Ocrevus Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE:AND) and Polpharma Biologics International AG today announced a global licensing agreement granting…
benzinga.com Teva Pharma And Polpharma Biologics Announce Global Licensing Agreement Granting Teva Exclusive Rights To Commercialize Both Formulations Of Polpharma Biologics’ Proposed Biosimilar To Ocrevus, Upon Regulatory Approval Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances…
benzinga.com Teva Pharmaceutical Industries Subsidiary And Medincell Says European Medicines Agency Has Accepted The Marketing Authorization Application For Olanzapine Long-Acting Injectable (TEV-'749) For The Treatment Of Schizophrenia In Adults The olanzapine long-acting injectable (TEV-'749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.If approved, TEV-‘749 could help fill a…- benzinga.com ETFs: Looking For Strength in All The Right Places (XLY, FCG, VNM)
- benzinga.com New Kids On The Block: Global X's Top New ETFs
benzinga.com Five Multi-Country EM ETFs To Consider - benzinga.com Global X Tops $1.5 Billion In AUM
benzinga.com February ETF Stats Part I 
benzinga.com Global X To Introduce 7 New Global ETFs